Myriad Genetics Inc

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.myriad.com

Earnings Score
Moat Score
Safety Score

Market Cap $656.36M
PE -5
Debt $39.60M
Cash $111.90M
EV $584.06M
FCF -$27.70M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$127.30M
EBIT	-$123.50M
ROE	-18%
ROA	-12%
FCF	-$27.70M
Equity	$701.10M
Growth Stability	-311%
PE	-5.16
PB	0.94
P/FCF	-23.7
P/S	0.78
Price/Cash	0.17
Debt/Equity	0.06
Debt/FCF	-1.43
Net Margins	-15%
Gross Margins	70%
Op. Margins	-15%
Earnings CAGR	-0%
Sales Growth YoY	7%
Sales Growth QoQ	-1%
Sales CAGR	-1%
FCF CAGR	-3%
Equity CAGR	0%
Earnings Stability	0
Earnings Growth YoY	36%

Earnings Growth QoQ	92%
Sales CAGR 5Y	16%
Equity CAGR 5Y	-6%
Earnings CAGR 3Y	9%
Sales CAGR 3Y	9%
Equity CAGR 3Y	-11%
Market Cap	$656.36M
Revenue	$837.60M
Assets	$1.03B
Total Debt	$39.60M
Cash	$111.90M
Shares Outstanding	90.28M
EV	584.06M
Earnings Score	6%
Moat Score	4%
Safety Score	35%
Final Score	15%
Working Capital	133.9M
Current Ratio	1.82
Gross Profit	$585.40M
Shares Growth 3y	5%
Equity Growth QoQ	-4%
Equity Growth YoY	-10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

SEC Filings

Direct access to Myriad Genetics Inc (MYGN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Myriad Genetics Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Myriad Genetics Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%

Stability 0%

loading chart...

Myriad Genetics Inc Discounted Cash Flow

Fully customizable DCF calculator online for Myriad Genetics Inc.

Years

Calculation mode

= -$230M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$28M	-$27M	-$26M	-$25M	-$25M	-$24M	-$23M	-$23M	-$22M	-$21M	-$21M	-$209M
DCF		-$24M	-$22M	-$19M	-$17M	-$15M	-$13M	-$12M	-$10M	-$9.1M	-$8.1M	-$81M
Value	-$230M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	11%	17%	3%	17%	1%	-4%	-17%	-35%	-15%	-15%
ROA	-	19%	4%	10%	0%	-4%	-12%	-22%	-12%	-12%
ROE	-	17%	3%	14%	0%	-3%	-13%	-34%	-18%	-18%

Bad Net Margins (-15.2%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	1	0.09	3.13	0	-0	-0.22	-1.43	-1.43
Debt over Equity	-	-	0.13	0.01	0.22	0	0	0.05	0.06	0.06
Growth Stability	-	-	-	100%	5%	-52%	-311%	-	-	-311%

Good Debt/FCF ratio (-1.43)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.06)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-311%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2015	06/2016	06/2017	06/2018	06/2019	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	4%	2%	0%	10%	-19%	-2%	11%	11%	16%
Earnings YoY growth	-	56%	-83%	506%	-97%	-718%	312%	135%	-52%	-
Equity YoY growth	-	13%	4%	24%	13%	-11%	-8%	-12%	-10%	-6%
FCF YoY growth	-	38%	-38%	7%	-30%	-100%	-76K%	15%	-84%	-